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Abstract
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Background: Given current evidence, the use of allopurinol for the
prevention of major cardiovascular events (acute cardiovascular syndrome (ACS) or cardiovascular mortality) in patients undergoing coronary artery bypass graft (CABG), after index ACS or heart failure
remains unknown.
Methods: Multiple databases were queried to identify studies comparing the efficacy of allopurinol in patients undergoing CABG, after
ACS or heart failure. The unadjusted odds ratio (OR) was calculated
using a random effect model.
Results: A total of nine studies comprising 850 patients (allopurinol
480, control 370) were identified. The pooled OR of periprocedural
ACS (OR: 0.25, 95% confidence interval (CI): 0.06 - 0.96, P = 0.05)
and cardiovascular mortality (OR: 0.22, 95% CI: 0.07 - 0.71, P =
0.01) was significantly lower in patients receiving allopurinol during
CABG compared to patients in the control group. The overall number
needed to treat (NNT) to prevent one ACS event was 11 (95% CI: 7 28), while the NNT to prevent one death was 24 (95% CI: 13 - 247).
By contrast, the odds of cardiovascular mortality in the allopurinol
group were not significantly different from the control group in patients on long-term allopurinol after ACS or heart failure (OR: 0.33,
95% CI: 0.01 - 8.21, P = 0.50) and (OR: 1.12, 95% CI: 0.39 - 3.20, P
= 0.83), respectively. Similarly, the use of allopurinol did not reduce
the odds of recurrent ACS events at 2 years (OR: 0.32, 95% CI: 0.03
- 3.18, P = 0.33).
Conclusions: Periprocedural use of allopurinol might be associated
with a significant reduction in the odds of ACS and cardiovascular
mortality in patients undergoing CABG. Allopurinol, however, offers
no long-term benefits in terms of secondary prevention of ACS or
mortality. Larger scale studies are needed to validate our findings.
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Introduction
Approximately 50% of patients undergoing coronary artery
bypass graft (CABG) surgery have periprocedural reperfusion injury resulting in a considerable depression of the early
postsurgical cardiac function (myocardial stunning) [1]. PostCABG myocardial stunning was widely held to result from uncontrolled free radical activity and thought to be amenable to
anti-free radical therapy [2]. Given this, almost half the CABG
patients theoretically could benefit from the administration of
free oxygen radical scavengers. However, some clinical studies have failed to demonstrate convincing evidence on the production of free radicals during revascularization procedures.
The addition of locally active agents (anti-free radical) to the
cardioplegic solutions (used during the CABG procedure) has
yielded disappointing clinical outcomes [3, 4].
Several studies had found an increased level of systemic free
radical activity during and after CABG procedures when the
antioxidant defense mechanism of myocardium was thought to
be considerably impaired [3, 5]. It is, therefore, reasonable to
speculate that circulating free radical toxins when antioxidant
defenses are decreased produce myocardial stunning [5]. This
hypothesis provides a logical background for the limited, yet
controversial clinical benefits associated with the systemic administration of direct free radical scavenging agents such as allopurinol at times of myocardial ischemia [6, 7].
The proposed mechanisms of allopurinol include systemic
reduction of free radical activity by inhibition of the xanthine oxidase (a superoxide-generating enzyme), suppressing the secretion
of inflammatory mediators and increasing nitric oxide production
[8]. The later could also potentially reduce the incidence of acute
coronary syndrome (ACS), as was suggested by Huang et al [9].
These theoretical benefits have led to studies examining the utilization of allopurinol before CABG and for the secondary prevention of ACS. However, evidence of its efficacy is scarce and
controversial. Our study aims to bring consensus on the clinical
use of allopurinol in patients undergoing CABG or after an ACS.

Materials and Methods
A structured literature search of electronic databases, including
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Figure 1. Summary of the methodological quality of the included studies showing minimal risk of bias (red).

MEDLINE (PubMed, Ovid), EMBASE, clinicaltrials.gov, and
Cochrane, was performed using a combination of keywords
and medical subject headings (MeSH). The keyword “allopurinol” was combined with a list of MeSH terms including “ischemic heart disease,” “CAD,” “stable angina,” “myocardial
infarction,” “coronary artery disease,” “MI,” “heart failure,”
and “STEMI.” Databases were last accessed on March 2,
2019. Based on our research question, articles from the reference lists relevant to the clinical question were also screened
by an independent author (backward snowballing). All studies
enrolling patients age greater than 18 years and reporting the
role of allopurinol during CABG, post-ACS or in heart failure
were included. The primary efficacy endpoint was MI and cardiovascular mortality.
The statistical analysis was performed using the CochranMantel-Haenszel test under the random effect model to calculate pooled odds ratio (OR) for the endpoints. The estimated effect size was reported as a point estimate and 95%
confidence interval (CI). An alpha criterion of P value less
than 0.05 was considered statistically significant. If the eligibility of a study was dubious or influencing due to its large
sample size, a sensitivity analysis was performed. Higgins
I-squared (I2) statistic model was used to evaluate variations
in outcomes of included studies. I2 values of 50% or less
corresponded to low to moderate, and 75% or higher indicated large amounts of heterogeneity. The publication bias
was illustrated graphically with funnel plotting. All statistical
analysis was performed using the Cochrane Review Manager
version 5.3.
Quality assessment of the included studies
The methodological quality was performed by screening all
included articles for five different types of bias (selection, performance, detection, attrition, and reporting bias). The overall
quality of the included studies was high (Fig. 1). All included
clinical trials were randomized minimizing the risk of selection bias. Similarly, due to appropriate “allocation concealment” across most studies, the risk of sampling bias was low.
Rashid et al [10] failed to obtain allocation concealment and in
the study by Goicoechea et al [8], more than 10% of patients
were lost at follow-up, introducing some risk of selection and
attrition bias, respectively. Reporting bias across all studies
was reduced due to an adequate description of the study re-

sults. Similarly, the risk of detection and performance bias was
minimal. The individual study and overall bias summaries are
reported in Figures 1 and 2.

Results
A systematic search of the literature identified 1,371 articles.
Following the removal of irrelevant and duplicate items, 80
articles were deemed relevant for full text review. We further
excluded 71 articles based on selection criteria; nine clinical
trials qualified for final analysis (Table 1) [6, 8-15]. All included trials enrolled patients undergoing CABG or having ACS
or heart failure. The preferred reporting items for systematic
reviews and meta-analyses (PRISMA) flow diagram is shown
in Figure 3.
A total of 850 patients were included; 480 in the allopurinol and 370 in the placebo or control group. The mean age
was 63.4 years, comprising 79% male patients. Of the total
population, 84% of patients had a history of hypertension and
32% had diabetes mellitus. There was no significant difference in the baseline characteristics of the two groups across
most of the studies. A significant amount of heterogeneity was
observed in the selection criteria and follow-up durations of
the included studies. Six of the included studies compared the
utility of allopurinol in CABG patients, two trials studied the
efficacy of allopurinol in the secondary prevention of ACS and
one randomized controlled trial (RCT) studied the effect of allopurinol on heart failure-related hospitalizations. Huang et al
[9] included patients after an acute event of ACS, while Goicoechea et al [8] recruited patients with chronic kidney disease
(CKD). The follow-up period in patients undergoing CABG
was up to 30 days post-procedure, while it was 2 years in studies on ACS and 24 weeks in the study on heart failure patients.
The daily dose of allopurinol ranged from 100 mg daily (for
CKD patients in Goicoechea’s study) to 600 mg daily or 300
mg twice a day. The detailed baseline characteristics are given
in Table 1 [6, 8-15].
Allopurinol for periprocedural in CABG patients
Five studies comprising 215 patients (allopurinol 106, control
109) contributed to this comparison. Patients receiving allopurinol during the CABG procedure had significantly lower odds
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The odds of cardiovascular mortality (OR: 0.33, 95% CI: 0.01
- 8.21, P = 0.50) or recurrent ACS events (OR: 0.32, 95% CI:
0.03 - 3.18, P = 0.33) in the allopurinol group were not significantly different from the control group. Similarly, in patients
with a diagnosed heart failure, the use of allopurinol for 24
weeks offered no benefits in terms of lower ACS events (OR:
1.12, 95% CI: 0.39 - 3.20, P = 0.83) (Fig. 5).
Publication bias
The funnel plot showed asymmetry, indicating the possibility
of publication bias. One study has shown the graphical violation of the midline, as depicted in Figure 6. One can argue
that it is difficult to differentiate between “findings by chance”
and “real asymmetry,” as only six articles were assessed for
potential publication bias. As pointed by Sterne et al in a study
of fewer than 10 articles, it is difficult to differentiate between
real asymmetry and findings merely by chance [16].

Discussion

Figure 2. Detailed methodological quality assessment of the included
studies showing minimal risk of bias (red).

of periprocedural ACS events by 75% compared to patients on
placebo or no medication (OR: 0.25, 95% CI: 0.06 - 0.96, P =
0.05) (Fig. 1). On Higgin’s equation, there was no heterogeneity in the outcomes of the included studies (I2 = 0%) (Fig. 2).
The study by Johnson et al [6] also showed that allopurinol
could significantly decrease the odds of periprocedural cardiovascular mortality (OR: 0.22, 95% CI: 0.07 - 0.71, P = 0.01)
(Fig. 4).
A sensitivity analysis of periprocedural CABG-related
ACS events based on the exclusion of the study by Rashid et
al [10] showed no significant difference between two groups
(OR: 0.37, 95% CI: 0.10 - 1.32, P = 0.13). This indicates that
although all studies showed a numerical advantage of lower
ACS events in the allopurinol group, the statistically beneficial
findings were actually driven by one study.
228

Our results revealed that prophylactic use of allopurinol in patients undergoing CABG could potentially decrease periprocedural MI and cardiovascular mortality. These findings, however, should be interpreted with caution, given that they were
driven only by one study (Rashid et al) [10]. On sensitivity
analysis, there was no significant difference in the periprocedural MI event rate between patients receiving allopurinol and
those on the placebo. Similarly, Johnson et al was the only
study to demonstrate a significantly lower rate of periprocedural mortality in CABG patients on allopurinol [6]. Other
studies compared the long-term efficacy of allopurinol in patients with CKD, ACS and congestive heart failure (CHF).
The risk of recurrent MI and cardiovascular mortality at an extended follow-up duration of 2 years was found to be identical
between patients in allopurinol and control groups [8, 9, 11].
On review, we found a significant amount of heterogeneity in the inclusion criteria and outcomes of the included
studies. Gimpel et al recruited 22 CABG patients (control 14,
allopurinol eight) to determine the possibility of myocardial
protection against reperfusion injury by allopurinol [14]. On
a multivariate analysis adjusted for potential effect modifiers,
there was no difference recorded between the two groups. This
study, however, was designed to calculate the effect of the inflammatory markers (leukotrienes), and was underpowered to
gauge the hard clinical outcomes (MI and mortality). By contrast, Rashid et al included 90 CABG patients, half of which (n
= 45) received a loading dose of allopurinol in the perioperative period. Compared to the control arm, allopurinol had an
18% lower risk of perioperative MI. This numerical difference,
however, did not reach the level of statistical significance [10].
Taggart et al randomized 20 patients to receive allopurinol or to act as controls [12]. The primary endpoint measured
was the efficacy of myocardial protection determined by serial
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RCT
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RCT

RCT

RCT

RCT

RCT

RCT

Design

100

169

113

253

50

20

90

22

33

Total

50

89

57

128

25

10

45

8

18

50

80

56

125

25

10

45

14

15

Allopu- Placebo/
rinol
control

Post-CABG

CKD and
hyperuricemia

Heart failure and
uric acid > 9.5

Post-CABG

Post-CABG

Post-CABG

Post-CABG

Post-CABG

Population

600 mg daily × 2 weeks, ACS
then 200 mg daily

300 mg

100 mg

600 mg, 300
mg in CKD

300 mg

300 mg

300 mg

200 mg

200 mg

Dose

56

60

72

63

58

66

62

59

61

Mean
age

60%

84%

-

82%

84%

100%

76%

77%

94%

Men

-

-

-

78%

-

-

-

-

-

HTN

-

10%

38%

69%
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-

-

-

-
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Every week
for 2 years

30 days

23 ± 8
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12 and 24
week

During
CABG only

72 h postCABG

-

10 days
post-CABG

-

Follow-up
(months)

RCT: randomized controlled trial; CABG: coronary artery bypass graft; CKD: chronic kidney disease; ACS: acute cardiovascular syndrome; HTN: hypertension; DM: diabetes mellitus.

Castelli et al,
1995 [15]

Author

1

Study
ID

Table 1. Characteristics of the Included Studies

Ullah et al
Cardiol Res. 2020;11(4):226-232

Articles © The authors | Journal compilation © Cardiol Res and Elmer Press Inc™ | www.cardiologyres.org

229

Allopurinol in Cardiovascular Diseases

Figure 3. PRISMA flow diagram of the included studies. PRISMA: preferred reporting items for systematic reviews and meta-analyses.

measurement of high sensitive cardiac troponin T (cTnT), creatine kinase (CK)-MB and myoglobin. This study also demonstrated no significant difference in the levels of pre- and postoperative cardiac biomarkers or electrocardiogram (ECG) (no
evidence of perioperative infarction) at 1, 6, 24, and 72 h after
CABG procedure [12]. Coghlan et al subsequently showed
that compared to the control group, allopurinol pretreatment in
CABG patients could significantly reduce the use of inotropic
support (n = 5/25 vs. 13/25, P ≤ 0.01) and can increase the cardiac index (P ≤ 0.004) after the surgery [13]. These differences,
however, did not translate into the clinical outcomes. Similar
to the study of Taggart et al [12], an identical periprocedural
MI rate was observed between the two groups [13]. Unfortunately, the comparison groups in all these studies were far from
homogeneous, and the procedures performed were by different

Cardiol Res. 2020;11(4):226-232
surgeons. Similarly, the duration of an ischemic event, degree
of myocardial impairment and number of diseased coronary
vessels were not consistent.
Johnson et al hurdled these limitations by recruiting 169
patients (allopurinol 89, placebo 80), matched for their surgical risk factors and baseline comorbidities [6]. Contrary to previous studies, the in-hospital mortality rate in the allopurinol
group (n = 4/89, 4%) was significantly lower than the placebo
group (n = 14/80, 18%, P = 0.014). Similarly, cardiac performance, scored by cardiac index and the need for mechanical
and inotropic support, significantly favored the allopurinol
group [6].
Three studies compared the utility of allopurinol for the
secondary prevention of ACS and cardiovascular mortality.
Huang et al recruited 100 patients (50 in each group) with the
diagnosis of the ACS. At 1 month, the total effective rate of
angina pectoris and ECG in the allopurinol group patients was
93% and 96%, significantly better than the placebo arm (76%
and 82%), respectively. The number of patients with stent implantation and cardiovascular mortality was not significantly
different between the two groups at 2 years [9]. Givertz et al
randomized 253 patients with symptomatic heart failure (ejection fraction less than 40%) into allopurinol and a placebo
group [11]. At 24 weeks, there was no significant difference in
the clinical status of cardiomyopathy and ejection fraction between the allopurinol- and placebo-treated patients. The number of MI events was also identical between the two groups.
This study could not exclude the possibility that a study on
higher dose of allopurinol or long-term follow-up of a more
homogeneous group of high-risk patients would have demonstrated significant reductions in heart failure-related mortality
[11]. In the RCT by Goicoechea et al, 113 patients (allopurinol
57, control 56) with CKD (estimated glomerular filtration rate
(eGFR) < 60 mL/min) were included [8]. Allopurinol treatment slowed down kidney disease progression but showed
no significant difference in the 2-year rate of cardiovascular
mortality. Other notable cardiovascular events in the allopurinol and control groups included heart failure in eight patients,
ischemic coronary events, cerebrovascular accidents, peripheral arteriopathy, and arrhythmias in seven, five, one and one
patients, respectively [8].
The present study systematically stratified patients based
on their patient’s inclusion criteria and follow-up duration.
Briefly, allopurinol confers advantages over placebo if used
in conjunction with cardioplegic therapy during the CABG

Figure 4. Forest plot of CABG patients showing significantly lower odds of periprocedural myocardial infarction in the allopurinol
group compared to the control group. CABG: coronary artery bypass graft.
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Figure 5. Forest plot showing lower CABG related mortality and an identical odds of cardiovascular mortality in the allopurinol
group compared to the control group in patients with heart failure, CKD and after PCI. CABG: coronary artery bypass graft; CKD:
chronic kidney disease; PCI: percutaneous coronary intervention; 95% CI: 95% confidence interval.

procedure. Our study demonstrates that periprocedural MI and
cardiovascular mortality might be substantially lower with the
use of anti-free radical therapy. The long-term benefits of allopurinol could not be established in patients with a prior history of ACS, CKD, or heart failure.
Limitations
This meta-analysis was constrained by the limitations of the

included studies. Only seven underpowered studies were included in the final analysis, indicating that our overall results
were only modest in its statistical power. This, in addition to
the vast heterogeneity of the inclusion criteria, calls for caution
when interpreting the results of this meta-analysis. Patientlevel data were missing to determine the impact of baseline
comorbidities on the overall clinical outcomes. The dose-response relationship and subgroup analysis based on the treatment vs. “intention-to-treat” group was lacking in most of the
included studies, limiting our ability to calculate their predictive effects. Similarly, we could not account for the differential
use of other prophylactic medications (in cases of CABG) or
secondary preventive therapy (in post-ACS) patients between
the two groups. All studies primarily focused on the biochemical outcomes, while hard clinical endpoints (mortality and MI)
were recorded as secondary outcomes, potentially underpowering the overall results. The net clinical benefit of allopurinol
could not be ascertained as a significant amount of allopurinolinduced complications such as renal and liver failure were neglected. This can potentially reduce the precision of our estimated results.
Conclusions

Figure 6. Funnel plot showing a possibility of publication bias or findings merely by chance.

Allopurinol might potentially reduce the periprocedural adverse events, including MI and mortality in patients undergoing CABG. However, it has no long-term benefits in terms of
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secondary prevention of ACS and mortality in patients with
ACS, heart failure, or CKD. Larger scale studies are needed
to determine the true merits of allopurinol in cardiovascular
disease.
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